Thanks to visit codestin.com
Credit goes to link.springer.com

Skip to main content
Log in

Serotonin does not mediate anxiolytic effects of buspirone in the fear-potentiated startle paradigm: comparison with 8-OH-DPAT and ipsapirone

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The present study evaluated the role of various neurotransmitter systems in mediating buspirone's blockade of the fear-potentiated startle effect, where acoustic startle amplitude is normally increased in the presence of a light previously paired with a shock. Large lesions of the dorsal and median raphe nuclei or IP injections of the serotonin antagonists cinanserin (10 mg/kg) or cyproheptadine (5 mg/kg) did not alter fear-potentiated startle, nor did these treatments prevent buspirone (5 or 10 mg/kg SC) from blocking fear-potentiated startle. The 5-HT1A agonist 8-OH-DPAT (2.5–10.0) did not block fear-potentiated startle even at doses that produced a marked “5-HT syndrome”. Another 5-HT1A agonist, ipsapirone (10–20 mg/kg), blocked potentiated startle only at a very high dose (40 mg/kg).p-Chlorophenylalanine andp-chloroamphetamine did not alter fear-potentiated startle. Finally, pretreatment with the benzodiazepine receptor antagonist RO-15-1788 (1 mg/kg); the opiate antagonist naloxone (2 mg/kg) or the α2-adrenergic antagonist yohimbine (5 mg/kg) did not reduce fear-potentiated startle, nor did they prevent buspirone from blocking fear-potentiated startle. Taken together, the data do not support the hypothesis that buspirone's anxiolytic effects are mediated by actions at 5-HT1A receptors and more generally indicate that serotonergic neurons do not play an important role in fear-potentiated startle.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+
from £29.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Aghajanian GK, Sprouse JS, Rasmussen K (1987) Physiology of the midbrain serotonin system. In: Meltzer H, Bunney BS, Coyle JT, Davis K, Kopin IJ, Schuster CR, Shader RI, Simpson GM (eds) Psychopharmacology, the third generation of progress. Raven Press, New York

    Google Scholar 

  • Andrade R, Nicoll RA (1985) The novel anxiolytic buspirone elicits a small hyperpolarization and seduces serotonin responses at putative 5-HT1 receptors on hippocampal CA1 pyramidal cells. Soc Neurosci Abstr 11:597

    Google Scholar 

  • Archer TA (1982) Serotonin and fear retention in the rat. J Comp Physiol Psychol 96:491–516

    Google Scholar 

  • Berg WK, Davis M (1984) Diazepam blocks fear-enhanced startle elicited electrically from the brainstem. Physiol Behav 32:333–336

    Google Scholar 

  • Cassella JV, Davis M (1986) The design and calibration of a startle measurement system. Physiol Behav 36:377–383

    Google Scholar 

  • Cedarbaum JM, Aghajanian GK (1978) Afferent projections to the rat locus coeruleus as determined by a retrograde tracing technique. J Comp Neurol 178:1–16

    Google Scholar 

  • Commissaris RL, Rech RH (1982) Interactions of metergoline with diazepam, quipazine, and hallucinogenic drugs on a conflict behavior in the rat. Psychopharmacology 76:282–285

    Google Scholar 

  • Davis M (1979a) Diazepam and flurazepam: effects on conditioned fear as measured with the potentiated startle paradigm. Psychopharmacology 62:1–7

    Google Scholar 

  • Davis M (1979b) Morphine and naloxone: effects on conditioned fear as measured with the potentiated startle paradigm. Eur J Pharmacol 54:341–347

    Google Scholar 

  • Davis M, Redmond DE Jr, Baraban JM (1979) Noradrenergic agonists and antagonists: effects on conditioned fear as measured by the potentiated startle paradigm. Psychopharmacology 65:111–118

    Google Scholar 

  • deMontigny C, Blier P, Chaput Y (1984) Electrophysiologically-identified serotonin receptors in the rat CNS. Neuropharmacology 23:1511–1520

    Google Scholar 

  • Eison MS, Eison AS (1984) Buspirone as a midbrain modulator: anxiolysis unrelated to traditional benzodiazepine mechanisms. Drug Dev Res 4:109–119

    Google Scholar 

  • Eison AS, Eison MS, Stanley M, Riblet LA (1986) Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacol Biochem Behav 24:701–707

    Google Scholar 

  • Evans L, Moore G (1981) The treatment of phobic anxiety by zimelidine. Acta Psychiatr Scand 63:342–345

    Google Scholar 

  • Glasser T, Traber J (1983) Buspirone: action on serotonin receptors in calf hippocampus. Eur J Pharmacol 88:137–138

    Google Scholar 

  • Hitchcock JM, Davis M (1986) Lesions of the amygdala, but not of the cerebellum or red nucleus, block conditioned fear as measured with the potentiated startle paradigm. Behav Neurosci 100:11–22

    Google Scholar 

  • Hjorth S, Carlsson A (1982) Buspirone effects on central monoaminergic transmission — possible relevance to animal experimental and clinical findings. Eur J Pharmacol 83:299–303

    Google Scholar 

  • Jacobs BL (1976) Animal behavior model for studying central serotonergic synapses. Life Sci 19:777–786

    Google Scholar 

  • Kehne JH, Cassella JV, Davis M (1987) Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology 94:8–13

    Google Scholar 

  • Kilts CD, Commissaris RL, Cordon JJ, Rech RH (1982) Lack of central 5-hydroxytryptamine influence on the anticonflict activity of diazepam. Psychopharmacology 78:156–164

    Google Scholar 

  • Koczkas S, Holmberg G, Wedin L (1981) A pilot study of the effect of the 5-HT-uptake inhibitor, zimelidine, on phobic anxiety. Acta Psychiatr Scand 63:328–341

    Google Scholar 

  • Louilot A, LeMoal M, Simon H (1986) A study of the effects of buspirone, BMY 13805, and 1-PP on dopaminergic metabolism in the nucleus accumbens using in vivo voltammetry in freely moving rats. Life Sci 39:685–692

    Google Scholar 

  • Lucki I, Ward HR (1986) Antagonism of serotonin-mediated behaviors in rats by pretreatment with the non-benzodiazepine anxiolytics buspirone or ipsapirone. Soc Neurosci Abstr 12:1236

    Google Scholar 

  • Mauk MD, Peroutka SJ, Kocsis JD (1985) Modulation of synaptic transmission in the hippocampus produced by novel anxiolytics (Buspirone, TVX-Q & DPAT). Soc Neurosci Abstr 11:135

    Google Scholar 

  • McMillen BA, Mattiace LA (1983) Comparative neuropharmacology of buspirone and MJ-13805, a potential anti-anxiety drug. J Neural Transm 57:255–265

    Google Scholar 

  • McMillen BA, McDonald CC (1983) Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat. Neuropharmacology 22:273–278

    Google Scholar 

  • McMillen BA, Matthews RT, Sanghera MK, Shepard PD, German DC (1983) Dopamine receptor antagonism by the novel antianxiety drug, buspirone. J Neurosci 3:733–738

    Google Scholar 

  • Murphy JE (1978) Mianserin in the treatment of depressive illness and anxiety states in general practice. Br J Clin Pharmacol [Suppl 1] 5:81–85

    Google Scholar 

  • Ogren SO (1982a) Central serotonin neurones and learning in the rat. In: Osborne NN (ed) Biology of serotonergic transmission. Wiley, New York, pp 317–334

    Google Scholar 

  • Ogren SO (1982b) Forebrain serotonin and avoidance learning: behavioural and biochemical studies on the acute effect ofp-chloroamphetamine on one-way active avoidance learning in the male rat. Pharmacol Biochem Behav 16:881–895

    Google Scholar 

  • Ogren SO (1985) Central serotonin neurones in avoidance learning: interactions with noradrenaline and dopamine neurones. Pharmacol Biochem Behav 23:107–123

    Google Scholar 

  • Ogren SO, Johansson C (1985) Separation of the associative and non-associative effects of brain serotonin released by p-chloroamphetamine: dissociable serotoninergic involvement in avoidance learning, pain and motor function. Psychopharmacology 86:12–26

    Google Scholar 

  • Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346:205–230

    Google Scholar 

  • Peroutka SJ (1985) Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors. Biol Psychiatry 20:971–979

    Google Scholar 

  • Pich EM, Samanin R (1986) Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology 89:125–130

    Google Scholar 

  • Reynolds LS, Seymour PA, Heym J (1986) Inhibition of the behavioral effects of 8-OH-DPAT by the novel anxiolytics buspirone, gepirone and isapirone. Soc Neurosci Abstr 12:481

    Google Scholar 

  • Riblet LA, Taylor DP, Eison MS, Stanton HC (1982) Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 43:11–16

    Google Scholar 

  • Sanghera MK, German DC (1983) The effects of benzodiazepine and non-benzodiazepine anxiolytics on locus coeruleus unit activity. J Neural Transm 57:267–279

    Google Scholar 

  • Shopsin B, Friedman E, Gershon S (1976) Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 33:811–819

    Google Scholar 

  • Skolnick P, Weissman BA, Youdim MBH (1985) Monoaminergic involvement in the pharmacological actions of buspirone. Br J Pharmacol 86:637–644

    Google Scholar 

  • Soubrie P (1986) Reconciling the role of central serotonin neurons in human and animal behavior. Behav Brain Sci 92:319–364

    Google Scholar 

  • Stanton HC, Taylor DP, Riblet LA (1981) Buspirone — an anxioselective drug with dopaminergic action. In: Chronister RB, DeFrance JF (eds) The neurobiology of the nucleus accumbens. Haer Institute, Brunswick, ME, pp 316–321

    Google Scholar 

  • Taylor DP, Riblet LA, Stanton HC, Eison AS, Eison MS, Temple DL Jr (1982) Dopamine and antianxiety activity. Pharmacol Biochem Behav 17:25–35

    Google Scholar 

  • Temple DL Jr, Yevich JP, New JS (1982) Buspirone: chemical profile of a new class of anxioselective agents. J Clin Psychiatry 43:4–9

    Google Scholar 

  • Tricklebank MD, Forler C, Fozard JR (1984) The involvement of subtypes of 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino) tetralin in the rat. Eur J Pharmacol 106:271–282

    Google Scholar 

  • VanderMaelen CP, Matheson GK, Wilderman RC, Patterson LA (1986) Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug. Eur J Pharmacol 129:123–130

    Google Scholar 

  • Witkin JM, Barrett JE (1986) Interaction of buspirone and dopaminergic agents on punished behavior of pigeons. Pharmacol Biochem Behav 24:751–756

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davis, M., Cassella, J.V. & Kehne, J.H. Serotonin does not mediate anxiolytic effects of buspirone in the fear-potentiated startle paradigm: comparison with 8-OH-DPAT and ipsapirone. Psychopharmacology 94, 14–20 (1988). https://doi.org/10.1007/BF00735873

Download citation

  • Received:

  • Revised:

  • Issue date:

  • DOI: https://doi.org/10.1007/BF00735873

Key words